Jean Quancard
Basel, BS 4002, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Identification of TAK-756, A Potent TAK1 Inhibitor for the Treatment of Osteoarthritis through Intra-Articular Administration.
Journal: Journal of medicinal chemistry
Published: November 22, 2024
The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Phenotypic Drug Discovery.
Journal: ChemMedChem
Published: January 18, 2021
Discovery of Potent, Highly Selective, and In Vivo Efficacious, Allosteric MALT1 Inhibitors by Iterative Scaffold Morphing.
Journal: Journal of medicinal chemistry
Published: November 30, 2020
Optimization of the In Vivo Potency of Pyrazolopyrimidine MALT1 Protease Inhibitors by Reducing Metabolism and Increasing Potency in Whole Blood.
Journal: Journal of medicinal chemistry
Published: November 20, 2020
Pharmacological Inhibition of MALT1 Protease Leads to a Progressive IPEX-Like Pathology.
Journal: Frontiers in immunology
Published: January 17, 2020
Requirement of Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 Protease Activity for Fcγ Receptor-Induced Arthritis, but Not Fcγ Receptor-Mediated Platelet Elimination, in Mice.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: October 20, 2019
N-aryl-piperidine-4-carboxamides as a novel class of potent inhibitors of MALT1 proteolytic activity.
Journal: Bioorganic & medicinal chemistry letters
Published: February 20, 2018
An allosteric MALT1 inhibitor is a molecular corrector rescuing function in an immunodeficient patient.
Journal: Nature chemical biology
Published: December 12, 2017
The T-cell fingerprint of MALT1 paracaspase revealed by selective inhibition.
Journal: Immunology and cell biology
Published: May 16, 2017
Last Updated: 09/26/2026